Scandinavian ChemoTech AB (publ) announced agreement involves a rental installation at Asirvatham Speciality Hospital in Madurai, a medium-sized private hospital. The estimated revenues for this agreement, once the system is fully implemented, is at least EUR 50.000, with a potential to reach over EUR 100.000 per year. This amount is significantly higher compared to the projection per installation made by ChemoTech when the marketing activities in India started, meaning that estimated future revenues have been revised upwards.

Asirvatham Speciality Hospital, treats approximately 2000 cancer patients every month. After the completed training and installations of the IQwave(TM) Tumour Specific Electroporation (TSE) systems, relating to the three signed contracts, expect the use of TSE in India to grow quickly as more case reports will be able to get published.